SKU: Z-Path-GT-QU-JAK2-617
Interested in this product?
Please contact us to place an order.
quasa (Quantitative Allele Specific Amplification) for the detection of rare mutations. In cancer, acquired mutations are of diagnostic, prognostic and therapeutic significance. However, these mutations can be present at a very low overall level as a proportion of the total DNA in the sample. quasa kits give specific and sensitive detection down to low copy numbers in the presence of competing wild type DNA. Kits are quantitative and sensitive down to 0.1%. Full details of the quasa method are available in the handbook.
quasa kits are supplied with their own mastermix which is essential for kit performance. Packaged, optimised and ready to use. Expect Better Data.
Product features
genesig® kits are sold for research use only and are not licensed for diagnostic procedures.
Kit contents:
Primer and multiplex probe mix - wildtype/variants (50 reactions)
Positive controls - wildtype/variants
quasa mastermix (50 reactions)
RNAse/DNAse free water
Vaz, D.1. PB2202 VALIDATION OF THE PRIMERDESIGN® QUANTITATIVE ALLELE SPECIFIC AMPLIFICATION KIT FOR THE DETECTION OF THE JAK2V617F MUTATION. HemaSphere 3(S1):p 987, June 2019. | DOI: 10.1097/01.HS9.0000567288.78521.f3
PB2202 VALIDATION OF THE PRIMERDESIGN® QUANTITATIVE ALLELE S... : HemaSphere (lww.com)
Not open access, but looks like they used our kit based on this report: content (wits.ac.za)
Chatambudza M, Skhosana L, Ketseoglou I, Wiggill T. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms. Clin Lab. 2021 Nov 1;67(11). doi: 10.7754/Clin.Lab.2021.210236. PMID: 34758219.
PB2202 VALIDATION OF THE PRIMERDESIGN® QUANTITATIVE ALLELE SPECIFIC AMPLIFICATION KIT FOR THE DETECTION OF THE JAK2V617F MUTATION
Vaz, D.1
Author Information
HemaSphere 3(S1):p 987, June 2019. | DOI: 10.1097/01.HS9.0000567288.78521.f3
PB2201 PROGRESS AND SURVIVAL IN TRIPLE NEGATIVE PRIMARY MYELOFIBROSIS PATIENTS
Potre, C.1; Borsi, E.1; Samfireag, M.1; Pescaru, M.1; Potre, O.1
Author Information
HemaSphere 3(S1):p 986-987, June 2019. | DOI: 10.1097/01.HS9.0000567284.78521.cc
Ask our friendly experts your question and we'll respond within one business day.